Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan

Summary

This study will be conducted in a single center, open-label study with a single group fixed sequence design to evaluate the effect of repeated oral administration of 600 mg RIF(Rifampicin) given once daily over 11 days on the single oral dose pharmacokinetics of VPR(Vilaprisan) and on MDZ(Midazolam) as a reference (probe) substance.

Timeline

Start

2016-11-10

Primary completion

2017-01-27

Completion

2017-04-11

Drugs

Indications